Matthew Maurer
Columbia University Medical Center
39 Papers
85 Citations
Matthew Maurer is an academic researcher from Columbia University Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 18, co-authored 39 publications. Previous affiliations of Matthew Maurer include Columbia University.
Chat about Author
Papers
PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma
Lao H. Saal,Karolina Holm,Matthew Maurer,Lorenzo Memeo,Tao Su,Xiaomei Wang,Jennifer S. Yu,Per-Uno Malmström,Mahesh Mansukhani,Jens Enoksson,Hanina Hibshoosh,Åke Borg,Ramon Parsons +12 more
TL;DR: Mutation of PIK3CA is frequent, occurs early in carcinoma development, and has prognostic and therapeutic implications and the association between ERBB2 overexpression and Pik3CA mutation implies that more than one input activating the PI3K/AKT pathway may be required to overcome intact PTEN.
938
A secreted PTEN phosphatase that enters cells to alter signaling and survival.
Benjamin D. Hopkins,Barry Fine,Nicole Steinbach,Nicole Steinbach,Meaghan Dendy,Zachary Rapp,Jacquelyn Shaw,Jacquelyn Shaw,Kyrie Pappas,Kyrie Pappas,Jennifer S. Yu,Cindy Hodakoski,Sarah M. Mense,Joshua U. Klein,Joshua U. Klein,Sarah Pegno,Maria Luisa Sulis,Maria Luisa Sulis,Hannah E. Goldstein,Hannah E. Goldstein,Benjamin Amendolara,Benjamin Amendolara,Liang Lei,Liang Lei,Matthew Maurer,Matthew Maurer,Jeffrey N. Bruce,Peter Canoll,Peter Canoll,Hanina Hibshoosh,Hanina Hibshoosh,Ramon Parsons +31 more
TL;DR: A 576–amino acid translational variant of PTEN, termed PTEN-Long, that arises from an alternative translation start site 519 base pairs upstream of the ATG initiation sequence, adding 173 N-terminal amino acids to the normal PTEN open reading frame may have therapeutic uses.
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Qing-Bai She,Qing-Bai She,Sofia K. Gruvberger-Saal,Sofia K. Gruvberger-Saal,Matthew Maurer,Yilun Chen,Mervi Jumppanen,Tao Su,Meaghan Dendy,Ying Ka Ingar Lau,Lorenzo Memeo,Hugo M. Horlings,Marc J. van de Vijver,Jorma Isola,Hanina Hibshoosh,Neal Rosen,Ramon Parsons,Lao H. Saal,Lao H. Saal +18 more
TL;DR: This study emphasizes the importance of PI3K/PTEN pathway activity in ER-negative and basal-like breast cancer and supports the future clinical evaluation of combining EGFR andPI3K pathway inhibitors for the treatment of BLBC.
Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53.
TL;DR: There are two response elements for p53 in the promoter of the gene for the cyclin-dependent kinase inhibitor p21 and a response element in the human cdc25C promoter is bound by p53 with properties similar to the 3' site.
Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer
Kevin Kalinsky,Katherine D. Crew,Susan Refice,Tong Xiao,Antai Wang,Sheldon Feldman,Bret Taback,Aqeel Ahmad,Serge Cremers,Hanina Hibshoosh,Matthew Maurer,Dawn L. Hershman +11 more
TL;DR: A presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer patients observed reductions in other relevant biomarkers, including BMI, cholesterol, and leptin.